Bud Mishra pursues finance, genetic and therapeutic avenues in cancer research

Professor of Computer Science Bud Mishra has been involved in several recent studies that cast light on a diverse issues related to cancer research.

New Method Seeks to Diminish Risk, Maximize Investment in Cancer “Megafunds”
Recognizing the high research and development costs for drugs to combat cancer, Bud and a team of researchers from Saudi Arabia’s King Abdullah University of Science and Technology, the University of Lyon, France and the Baltimore-based company, InSilico Medicine, have devised a method to maximize investment into these undertakings by spotting which efforts are the most scientifically viable. Check out the project, published in the journal Oncotarget here.

Mishra was also co-senior author on a groundbreaking study with colleagues from NYU Langone, including Howard Hughes Medical Institute investigator Evgeny Nudler, PhD, doctoral student and lead author Justin Jee, and other collaborators in Langone’s Department of Biochemistry and Chemical Pharmacology. The paper, which describes a New DNA Sequencing Method Precise Enough to Reveal Hidden Mechanisms by which Bacteria Resist Antibiotics, appeared in the June 22 issue of Nature.

Colleagues Develop Method to Map Cancer Progression
Bud and a team from the University of Edinburgh, the Catalan Institute of Oncology-IDIBELL, the University of Barcelona, and the University of Milan-Bicocca have devised a computational method of mapping cancer progression which offers new insights into the factors that spur the disease as well as new ways of selecting effective therapies. The study appeared in the June 28, 2016 PNAS.